Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...
Through the first three of five single ascending dose cohorts in healthy participants, there have been no treatment related adverse events. Dr. Frédéric Triebel, CSO of Immutep, said: “We are very ...
Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback